Rezolute receives breakthrough therapy designation from fda for ersodetug in the treatment of hypoglycemia due to tumor hyperinsulinism

Registrational study in patients with tumor hyperinsulinism (hi) expected to commence mid-year designation underscores need for therapies to treat severe hypoglycemia in the oncology setting redwood city, calif., may 05, 2025 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a late-stage rare disease company focused on treating hypoglycemia caused by hi, today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation (btd) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor hi.
RZLT Ratings Summary
RZLT Quant Ranking